Healthy Volunteer Clinical Trial
Official title:
Study of Tolerance, Biodistribution and Dosimetry of Fucoidan Radiolabeled by Technetium-99m
The development of an innovative imaging agent capable of non-invasively detecting vulnerable
plaques is a major objective of research in cardiovascular pathology. Such a tool would allow
for better identification of patients at risk of acute events. We showed that 99mTechnetium
(99mTc)-labeled fucoidan was able to target P-selectine expressed by activated platelets in
vitro in humans and in vivo in a model of abdominal aortic aorta thrombus and endocarditic
vegetations in rats.
One of the objectives of the Nanoathero program is the clinical translation of the
99mTc-fucoidan. As a first step, we will assess the safety, biodistribution and dosimetry of
this new radiopharmaceutical in humans.
The development of an innovative imaging agent capable of non-invasively detecting vulnerable
plaques is a major objective of research in cardiovascular pathology. Such a tool would allow
for better identification of patients at risk of acute events. We showed that
99mTechnetium-labelled fucoidan was able to target P-selectin expressed by activated
platelets in vitro in humans and in vivo in a model of abdominal aortic aorta thrombus and
endocarditic vegetations in rats.
NanoAthero is a monocenter, interventional, open-labeled, first-in-man study to evaluate
tolerance of 99mTc-Fucoïdane in healthy volunteers.
Healthy volunteers registered in the Bichat Centre for Clinical Investigations (CCI) will be
contacted by email to participate in the study. The selection visit will be organized by the
CCI according to the availability of the healthy volunteer.
V0: selection/inclusion visit: pre-audit of eligibility criteria, demographic data, medical
examination, clinical examination and measurement of vital signs, urinary pregnancy test for
women of childbearing potential, blood samples (hematology and biochemistry analyses) and
12-lead ECG.
V1: 99mTc-Fucoidan scintigraphy. The delay between the inclusion visit and the completion of
the scan is 30 ± 7 days. The visit will include verification and confirmation of the consent
of the healthy volunteer, clinical examination and measurement of vital signs, urinary
pregnancy test for women of childbearing age, blood samples (hematology and biochemistry
analyses) and 12-lead ECG.
Whole-body scintigraphic acquisitions will be performed 30 min, 90 min, 3 hours, 6 hours and
24 hours after intravenous administration of 99mTc-Fucoidan for the evaluation of
biodistribution and dosimetry. Vital signs will be monitored 5 min, 15 min, 30 min, 60 min,
90 min, 3 hours, 6 hours and 24 hours after intravenous administration of 99mTc-Fucoidan.
24-hour urine collection will be performed for dosimetry assessment.
V2: End of research visit will be carried out 7 ± 3 days after administration of
99mTc-Fucoidan, and will include medical interview, clinical examination, measurement of
vital signs, blood samples (hematology and biochemistry analyses) and 12-lead ECG.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06326723 -
Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT00001367 -
Diagnosis and History Study of Patients With Different Neurological Conditions
|
||
| Completed |
NCT02699710 -
Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT02231892 -
Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study
|
N/A | |
| Not yet recruiting |
NCT06441916 -
Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions
|
Phase 1 | |
| Completed |
NCT03771586 -
A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects
|
Phase 1 | |
| Not yet recruiting |
NCT06337422 -
Bioequivalence Study of Generic Celecoxib 200 mg Capsules
|
Phase 1 | |
| Completed |
NCT03302182 -
Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT05049343 -
Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants
|
Phase 1 | |
| Recruiting |
NCT01629108 -
Normal Values in Hearing and Balance Testing
|
||
| Completed |
NCT02947854 -
Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant
|
Phase 1 | |
| Completed |
NCT02534870 -
Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT02224053 -
Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01676584 -
A Study of Single Dose RO6811135 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01697436 -
A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets
|
Phase 1 | |
| Completed |
NCT01684891 -
A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers
|
Phase 1 | |
| Completed |
NCT01711762 -
A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers
|
Phase 1 | |
| Completed |
NCT01591850 -
A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01461967 -
A Study on Safety, Pharmacokinetics and Pharmacodynamics of RO5508887 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01433575 -
A Pharmacokinetic Study of RO4917838 in Healthy Chinese Volunteers
|
Phase 1 |